Wireless EEG Device Extends Ambulatory Seizure Monitoring to 30 Days

A wireless electroencephalogram system cleared for up to 30 days of continuous ambulatory seizure monitoring is now available for patients as young as 1 year old, according to a report in Neurology Today — a monitoring window that approaches the duration of implanted subcutaneous systems while remaining a non-invasive, scalp-based modality.

Thirty days matters clinically. For decades, the standard outpatient options for capturing epileptic events have been routine scalp EEG (20–40 minutes), multi-day ambulatory EEG (typically 3 to 7 days), and inpatient video-EEG monitoring in epilepsy units (usually 3 to 7 days, limited by bed availability and admission cost). Extending non-invasive scalp recording to a full month increases the probability of capturing interictal epileptiform abnormalities and rare seizures in a home setting, and it does so in a pediatric population — children from 12 months of age — where prolonged admissions are especially burdensome for families and where seizure frequencies and semiologies can be under-reported by caregivers.

The wireless form factor is the enabling feature. Conventional ambulatory EEG tethers patients to a recorder through a cable bundle and restricts normal activity; a wireless headset with onboard signal storage allows children to sleep, attend daycare or school, and move freely while the recording continues. That ecological validity is precisely what prolonged ambulatory monitoring is meant to deliver: seizure counts and circadian patterns recorded in the patient's real environment rather than in a monitoring unit, where medication withdrawal and hospital routines can distort the clinical picture.

For reading-room practice, a 30-day scalp recording changes workflow in several concrete ways. Review volume becomes the dominant constraint — a month of continuous data exceeds 700 hours of tracing, so electroencephalographers will rely on automated event-flagging, seizure-detection algorithms, and patient- or caregiver-triggered annotations to triage epochs for human review. Electrode maintenance across a month of wear raises technical questions the source does not address: impedance stability, electrode migration, and artifact burden from daily living will determine diagnostic yield more than in shorter studies. Technologists fitting the device on infants and toddlers will also need validated strategies for maintaining contact through sleep, feeding, and play.

The pediatric indication deserves emphasis. FDA clearance from age 1 signals that the agency reviewed safety and effectiveness data in very young children, a group often excluded from device indications. For pediatric epileptologists, prolonged home monitoring in this age group has historically required either repeated short studies or referral for invasive options; a non-invasive 30-day scalp system fills a practical gap in the diagnostic ladder between routine EEG and surgical-phase monitoring.

Several caveats follow from what the report does and does not specify. The announcement does not detail sensitivity and specificity figures for the device's detection software, montage configuration, channel count, or comparative performance against inpatient video-EEG — the reference standard for seizure localization and semiology classification. Clinicians should note that ambulatory recordings without synchronized video lose semiological information, limiting their use for localization in presurgical evaluation and making differentiation of epileptic from non-epileptic events dependent on EEG signature alone. Claims should remain anchored to what extended home recording demonstrably provides: longer capture windows, better seizure counting, and characterization of event frequency over time.

Cost and access questions also remain open in the source material. A 30-day monitoring period will prompt payers to compare its reimbursement pathway against multi-day ambulatory EEG admissions, and utilization review will likely focus on which patients justify a month of recording — candidates include those with infrequent events, uncertain epilepsy diagnoses after conventional workup, and children being considered for medication withdrawal after a seizure-free interval.

The report positions the device as FDA-cleared rather than investigational, meaning it enters clinical availability now, with post-market experience expected to clarify real-world diagnostic yield, artifact performance, and reviewer workload. How epileptology programs integrate month-long wireless recordings into their diagnostic algorithms — and whether event-detection software proves reliable enough to keep human review tractable — will determine whether 30-day ambulatory scalp EEG becomes routine practice or remains a niche tool for the diagnostically difficult case.